The recent adoption of novel drug classes, including sodium-glucose cotransporter 2 inhibitors, alongside sacubitril/valsartan, into first-line guideline-driven medical therapy shows early promise.46 Trials have shown that, in addition to preventing HF hospitalizations in people with CKD,47-49 longer term use of sodium-glucose cotransporter 2 inhibitors has the potential to delay progression of CKD once HF has developed.49 Wider benefits in patients with HFrEF include increased survival, reduced hospitalizations and symptoms, and improved HRQoL.32 This evidence concerns the gene SLC5A2 and chronic kidney disease.